Grant: Catalyst Grant: Prevention and Treatment of Illicit Substance Use
Université de Montréal
$100,000.00
Cannabis addiction and psychosis: a preclinical model
FY 2010-11
Summary
Cannabis is the most widely illicit drug consumed worldwide. In 2009, more than 10% of Canadians reported using it. If we consider the population between 14 and 24 year old, the percentage is more than two-fold higher (26.3%). For people with a diagnosis of schizophrenia, the prevalence of substance use is near 50% and the drug that they most consume is cannabis. Cannabis addiction has a significant detrimental impact on these individuals. Those that consume cannabis are younger and they more frequently experience an exacerbation of their symptoms. They are less compliant to their medication and they relapse more often which results in more frequent hospitalizations. For them, the prognosis is much worse than for those who do not consume drugs. Because cannabis addiction in schizophrenic patients has major detrimental impacts on the individuals, their relatives, the health system and society, it appears imperative to initiate basic research leading to the development of a pre-clinical model that will allow us to unveil the neural mechanisms that sub-serve the vulnerability to cannabis addiction in subjects with susceptibility to the development of schizophrenia-like psychosis. The present research project is thus aimed at:
- Developing and validating an adequate animal model
- Identifying neurobiological abnormalities that lead, in this model, to abnormal responses to
cannabinoids.
- Identifying the mechanisms by which these neurobiological abnormalities arise.
- Based on these findings: develop a psychotropic treatment that will reduce cannabis addiction and contribute to reduction of psychotic symptoms.
While these constitute the long term objective of this research, the present proposal focuses on validation of the model and initial studies of the neurobiological bases of abnormal responses to cannabinoids.
Department
Program
Catalyst Grant: Prevention and Treatment of Illicit Substance Use
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
223053
Name
Rompré Pierre-Paul
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Catalyst Grant: Prevention and Treatment of Illicit Substance Use
Projecttitle
Cannabis addiction and psychosis: a preclinical model
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Prevention and Treatment of Illicit Substance Use
Keyworddelim
Addiction; Animal Model; Cannabis; Electrophysiology; Endocannabinoids; Neurochemistry; Psychosis; Reward; Schizophrenia
Abstract
Cannabis is the most widely illicit drug consumed worldwide. In 2009, more than 10% of Canadians reported using it. If we consider the population between 14 and 24 year old, the percentage is more than two-fold higher (26.3%). For people with a diagnosis of schizophrenia, the prevalence of substance use is near 50% and the drug that they most consume is cannabis. Cannabis addiction has a significant detrimental impact on these individuals. Those that consume cannabis are younger and they more frequently experience an exacerbation of their symptoms. They are less compliant to their medication and they relapse more often which results in more frequent hospitalizations. For them, the prognosis is much worse than for those who do not consume drugs. Because cannabis addiction in schizophrenic patients has major detrimental impacts on the individuals, their relatives, the health system and society, it appears imperative to initiate basic research leading to the development of a pre-clinical model that will allow us to unveil the neural mechanisms that sub-serve the vulnerability to cannabis addiction in subjects with susceptibility to the development of schizophrenia-like psychosis. The present research project is thus aimed at:
- Developing and validating an adequate animal model
- Identifying neurobiological abnormalities that lead, in this model, to abnormal responses to
cannabinoids.
- Identifying the mechanisms by which these neurobiological abnormalities arise.
- Based on these findings: develop a psychotropic treatment that will reduce cannabis addiction and contribute to reduction of psychotic symptoms.
While these constitute the long term objective of this research, the present proposal focuses on validation of the model and initial studies of the neurobiological bases of abnormal responses to cannabinoids.
Competitiondate
201101
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rompré, Pierre-Paul
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Neurosc Mental Hlth &A~ $100,000~ $0~